Breo Ellipta (Vilanterol Trifenatate, Fluticasone Furoate)

What Is Breo Ellipta?

Breo Ellipta is a dual-action maintenance inhaler designed to support long-term control of chronic respiratory diseases. It contains two active ingredients:

• Fluticasone furoate – an inhaled corticosteroid (ICS)
• Vilanterol (as vilanterol trifenatate) – a long-acting beta₂-agonist (LABA)

This combination targets both inflammation and bronchoconstriction, two key drivers of symptoms in asthma and COPD. Breo Ellipta is administered once daily via the Ellipta dry powder inhaler device, supporting adherence and simplified treatment regimens.

Chronic obstructive pulmonary disease is a progressive condition characterised by airflow limitation, commonly caused by smoking and environmental exposure. According to the NHS overview of COPD, maintenance inhaler therapy plays a central role in reducing exacerbations and improving quality of life. Similarly, long-term inhaled corticosteroid therapy forms the cornerstone of asthma management, as outlined in the
NHS asthma guidance
.

Therapeutic Uses and Clinical Benefits

Breo Ellipta is prescribed for:

• Maintenance treatment of airflow obstruction in adults with COPD, including chronic bronchitis and emphysema
• Reduction of COPD exacerbations in patients with a history of flare-ups
• Maintenance treatment of asthma in adults whose condition is inadequately controlled with inhaled corticosteroids alone

With once-daily dosing, Breo Ellipta offers sustained 24-hour bronchodilation and anti-inflammatory activity. Many patients report improved lung function, fewer night-time symptoms and reduced reliance on rescue inhalers when used consistently.

How Breo Ellipta Works

Fluticasone Furoate – Anti-Inflammatory Action

Fluticasone furoate is a potent corticosteroid that acts locally within the lungs to suppress inflammatory mediators. In asthma and COPD, airway inflammation leads to swelling, mucus overproduction and increased airway sensitivity. By reducing this inflammation, fluticasone improves airway stability and decreases symptom frequency.

Vilanterol – Long-Acting Bronchodilation

Vilanterol stimulates beta₂-adrenergic receptors in the bronchial smooth muscle, resulting in relaxation and widening of the airways. Its long duration of action supports once-daily dosing and helps maintain airflow throughout the day and night.

The dual mechanism provides complementary control of both inflammatory and bronchoconstrictive components of chronic respiratory disease. Regulatory oversight in the UK is provided by the Medicines and Healthcare products Regulatory Agency (MHRA) , with European evaluation by the European Medicines Agency (EMA)
.

Available Strengths

Breo Ellipta is supplied in two strengths:

• 100 micrograms/25 micrograms (fluticasone furoate/vilanterol)
• 200 micrograms/25 micrograms

The appropriate dose depends on diagnosis and disease severity.

• COPD: 100/25 micrograms once daily
• Asthma: 100/25 or 200/25 micrograms once daily, depending on clinical need

Dosage and Administration

Breo Ellipta should be used once daily at the same time each day. Only one inhalation is required per dose.

Using the Ellipta Device

1. Open the cover fully until you hear a click.
2. Exhale away from the mouthpiece.
3. Seal your lips around the mouthpiece.
4. Inhale steadily and deeply.
5. Hold your breath for several seconds before exhaling slowly.
6. Close the inhaler.
7. Rinse your mouth with water and spit out.

Rinsing helps reduce the risk of oral candidiasis (thrush), a known side effect of inhaled corticosteroids.

Difference Between Breo Ellipta and Trelegy Ellipta

Breo Ellipta – Dual Therapy

Breo Ellipta contains two medicines: fluticasone furoate and vilanterol. It provides anti-inflammatory and bronchodilator effects suitable for patients who require dual therapy.

Trelegy Ellipta – Triple Therapy

Trelegy Ellipta includes an additional long-acting muscarinic antagonist (umeclidinium), offering triple therapy for patients requiring broader bronchodilation and symptom control.

Key Distinctions

• Active Components: Breo (ICS + LABA) vs Trelegy (ICS + LABA + LAMA)
• Clinical Scope: Breo for moderate disease; Trelegy for patients needing escalation
• Bronchodilation: Trelegy offers additional muscarinic receptor blockade

Selection between these inhalers should be based on symptom burden, exacerbation history and clinician assessment.

Possible Side Effects

Common adverse effects may include:

• Headache
• Throat irritation
• Hoarseness
• Upper respiratory tract infection
• Oral thrush

In COPD patients, inhaled corticosteroids may increase the risk of pneumonia. Rare but serious reactions include hypersensitivity and severe allergic responses. Seek urgent medical attention if breathing worsens suddenly after inhalation.

Important Warnings and Precautions

• Not for acute bronchospasm or sudden asthma attacks
• Do not exceed the prescribed dose
• Use caution in patients with cardiovascular disorders
• Monitor for signs of systemic corticosteroid effects

Patients should inform their clinician of all concurrent medicines, including systemic steroids and strong CYP3A4 inhibitors.

Buying Breo Ellipta Online

Purchasing Breo Ellipta from a licensed online pharmacy such as LifePath Meds may provide cost savings compared with certain local retail prices. Regulated pricing structures in some jurisdictions can reduce long-term expenditure for chronic therapy.

When ordering online:

• Ensure a valid prescription is required
• Confirm the pharmacy is properly licensed
• Verify product authenticity and storage standards

Coupons and Discount Programmes

Promotional offers, including codes such as Hello10 for first-time customers, may help reduce initial purchase costs. Bulk purchasing or subscription-based ordering may provide further savings.

Storage and Stability

• Store at 15°C to 25°C.
• Keep in original packaging to protect from moisture.
• Discard 6 weeks after opening or when the dose counter reads “0”.

Avoid exposure to excessive humidity or direct heat to maintain efficacy.

Further Information

For comprehensive prescribing details, consult the official product monograph: Breo Ellipta Product Monograph
.